{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:46:10Z","timestamp":1789785970443,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the past decade, the treatment of chronic myeloid leukemia (CML) has undergone a drastic evolution. The discovery and success of imatinib and second\u2010generation tyrosine kinase inhibitors have substantially increased the outcome for CML patients. The next step in medical and scientific research is to better understand the malignancy so as to eventually find a cure to eliminate all leukemic cells from patients. One of the key issues is about the resistance of the leukemic stem cells to tyrosine kinase inhibitors. Here, we briefly describe our current studies on CML resistance, and leukemic stem cell modeling and characterization.<\/jats:p>","DOI":"10.1002\/hon.2329","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T02:46:48Z","timestamp":1468982808000},"page":"420-423","source":"Crossref","is-referenced-by-count":2,"title":["What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?"],"prefix":"10.1002","volume":"35","author":[{"given":"Matthieu","family":"Lewis","sequence":"first","affiliation":[{"name":"Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218 University of Bordeaux  Bordeaux Gironde France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Copland","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences University of Glasgow  Glasgow Glasgow City Counsil UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Haematology\/Oncology \u201cL. and A. Ser\u00e0gnoli\u201d University of Bologna  Bologna Emilia-Romagna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Sadovnik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology Medical University of Vienna  Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bedel","sequence":"additional","affiliation":[{"name":"Bioth\u00e9rapie de Maladies G\u00e9n\u00e9tiques et Cancer, INSERM U1035 Universit\u00e9 de Bordeaux  Bordeaux Gironde France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Prost","sequence":"additional","affiliation":[{"name":"CEA Institute of Emerging Diseases and Innovative Therapies (iMETI)  F\u201092265 Fontenay\u2010aux\u2010Roses \u00cele de France France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Bergoni\u00e9 Institute  Bordeaux Gironde France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois\u2010Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218 University of Bordeaux  Bordeaux Gironde France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3619"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.03.013"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0216-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.1025256"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00103"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29587"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-47"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2320-4"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.185"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_7_15_1","first-page":"713","article-title":"Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long\u2010term dormancy","volume":"2","author":"Chomel J\u2010C","year":"2011","journal-title":"Oncogene"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.02.067"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.19"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009615666150225123712"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621110"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1113"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-666214"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-588855"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009073"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247005"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac6572"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-761-7_16"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0767"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000349"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15248"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2329","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:57:09Z","timestamp":1695488229000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/hon.2329"],"URL":"https:\/\/doi.org\/10.1002\/hon.2329","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}